Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Phenotyping of ex vivo expanded NK cells reveals unique transcriptomic and epigenetic signatures

Megan Zinsky, Natalie Holl, Jun Choe et al. Nov 03, 2025 pp. 2360-2360 10.1182/blood-2025-2360

Abstract Background: Natural Killer (NK) cells have powerful anti-tumor effects. NK cells expanded for adoptive transfer are commonly co-cul...

MRD-guided azacitidine maintenance improves outcomes in molecularly persistent pediatric core-binding factor AML: A retrospective cohort study

Chunping Wu, Yiqiao Chen, Chunxia Cai et al. Nov 03, 2025 pp. 7050-7050 10.1182/blood-2025-7050

Abstract Background: Relapse remains a major challenge in pediatric acute myeloid leukemia (AML), particularly in non-transplant-eligible pa...

A-319, a CD3xCD19 T cell engager, monotherapy for patients with refractory/relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL)

Jin Wang, Yong Guo, Qike Zhang et al. Nov 03, 2025 pp. 6853-6853 10.1182/blood-2025-6853

Abstract Introduction Blinatumomab has been approved to treat patients with B cell precursor acute lymphoblastic leukemia (B-ALL) with 28-da...

Association of platelet transfusion and clinical outcomes in chimeric antigen receptor T-cell therapy: Insights from a six-year nationwide analysis

Adamsegd Gebremedhen, Abdu Mohammed, Semere Tesfamariam et al. Nov 03, 2025 pp. 6690-6690 10.1182/blood-2025-6690

Abstract Background Chimeric Antigen Receptor (CAR) T-cell therapy is an established treatment for relapsed or refractory non-Hodgkin's lymp...

A retrospective analysis of outcomes of high-risk myelodysplastic syndrome patients treated with upfront decitabine/cedazuridine versus hypomethylating agents with venetoclax utilizing real-world data

Mohamed Zakee Mohamed Jiffry, Devashish Desai, Myungwoo Nam et al. Nov 03, 2025 pp. 2859-2859 10.1182/blood-2025-2859

Abstract Background: High-risk myelodysplastic syndromes (HR-MDS) carry a poor prognosis, with median overall survival u...

Graft-versus-HIV-reservoir reactivity: Long term HIV remission after allogeneic stem cell transplantation from a donor with active CCR5

Christian Gaebler, Samad Kor, Christina Allers et al. Nov 03, 2025 pp. 2484-2484 10.1182/blood-2025-2484

Abstract Background HIV cure is exceptionally rare and is documented in only six cases. All HIV cure cases were individu...

Reduced pulmonary function and posterior cerebral artery perfusion among Hodgkin lymphoma survivors.

Nicholas Phillips, Silu Zhang, Matthew Ehrhardt et al. Nov 03, 2025 pp. 5405-5405 10.1182/blood-2025-5405

Abstract Background/Purpose: Hodgkin Lymphoma (HL) survivors exposed to chest radiation and bleomycin are at increased risk for heart and lu...

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Ross McCauley, Amy Zhang, Vamsi Kota et al. Nov 03, 2025 pp. 2396-2396 10.1182/blood-2025-2396

Abstract Introduction: CD19-directed CAR T-cell (CAR-T) therapy has substantially improved clinical outcomes for adults with relapsed or ref...

In-hospital outcomes of hyponatremia in non-Hodgkin lymphoma patients: Insights from a 7-year national cohort study

Haziq Ahmad, Minahil Javaid, Najam Gohar et al. Nov 03, 2025 pp. 8051-8051 10.1182/blood-2025-8051

Abstract Background: Non-Hodgkin lymphoma (NHL) is one of the most common hematological malignancies in the United States with the mortality...

25-year trends in autoimmune neutropenia-related mortality in the United States: A national CDC wonder analysis (1999-2023)

Abdullah Bin Usman, Amna Amjad, Swapna Gangasani et al. Nov 03, 2025 pp. 1216-1216 10.1182/blood-2025-1216

Abstract Background: Autoimmune neutropenia (AIN) is a rare immune-mediated hematologic disorder characterized by periph...

A multimodal machine learning framework to predict treatment duration in multiple myeloma patients

Frederick Shi, Xinyi Yang, Juan Li et al. Nov 03, 2025 pp. 5715-5715 10.1182/blood-2025-5715

Abstract Introduction:Artificial intelligence (AI) and machine learning (ML) are increasingly used in oncology to enable personalized treatm...

Efficacy and Safety of cladribine combined with cytarabine and G-CSF in Eliminating Measurable Residual disease for Core-binding factor acute myeloid leukemia: A retrospective, single-arm, multicenter study

Qiuxiao Li, Xi Jia, Guopan Yu et al. Nov 03, 2025 pp. 6968-6968 10.1182/blood-2025-6968

Abstract Background Persistent measurable residual disease (MRD) in core-binding factor acute myeloid leukemia (CBF-AML) is closely associat...

Disaggregated outcomes of Asian Americans, Native Hawaiian and Pacific Islander populations with Acute Myeloid Leukemia

Erin Feliciano, Douglas Tremblay, Hannah Levavi et al. Nov 03, 2025 pp. 4624-4624 10.1182/blood-2025-4624

Abstract Introduction: Asian American, Native Hawaiian, and Pacific Islander (AANHPI) individuals represent one of the m...

High FDX1 expression enhances the sensitivity of multiple myeloma cells to elesclomol

Hongyan Zhao, Fen He, Ruixin Gao et al. Nov 03, 2025 pp. 7448-7448 10.1182/blood-2025-7448

Abstract Background:Copper is an essential micronutrient required for regular physiological functions in the body. Dysregulated copper metab...

Integrating genomic features for prognosis in Chinese patients  with B-cell lymphoma following R-CHOP therapy

Shi Han, Yongxian Hu, He Huang Nov 03, 2025 pp. 3670-3670 10.1182/blood-2025-3670

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Despite therapeutic advancemen...

Behind the blood-brain barrier: Contemporary screening practice patterns and trends of central nervous system involvement in acute myeloid leukemia treated with intensive regimens and hypomethylating agent/venetoclax

Jamila Mammadova, Melanie Naranjo, Sarah Profitt et al. Nov 03, 2025 pp. 1621-1621 10.1182/blood-2025-1621

Abstract Background: Patients (pts) with newly diagnosed acute myeloid leukemia (AML) with WBC>40 x103/µL, FLT3-ITD/KD mutations (FLT...

Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation

Diego Adrianzen Herrera, Jacob Ambrose, Andrew Belli et al. Nov 03, 2025 pp. 4606-4606 10.1182/blood-2025-4606

Abstract Introduction: TP53 mutations (TP53m) are observed in ~10% of patients (pts) with myelodysplastic syndromes (MDS) and constitute a h...

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Zena Komrokji, Najla Al Ali, Zhuoer Xie et al. Nov 03, 2025 pp. 3856-3856 10.1182/blood-2025-3856

Abstract Introduction Elevated endogenous serum erythropoietin level (EPO) is a biomarker of erythropoiesis and is used in clinical practice...

Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis

Ana Oliver, Celso Arrais-Rodrigues, Luis Mario Villela Martinez et al. Nov 03, 2025 pp. 3908-3908 10.1182/blood-2025-3908

Abstract Background: Chronic lymphocytic leukemia (CLL) exhibits diverse clinical manifestations, and access to diagnost...

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

Ola Landgren, James Hoffman, Abhishek Pandey et al. Nov 03, 2025 pp. 251-251 10.1182/blood-2025-251

Abstract Introduction Advances in newly diagnosed multiple myeloma (MM) have resulted in high rates of MRD- negativity independent of transp...

Evaluation of outcomes by line of therapy in marginal zone lymphoma: Real-world evidence from 10 US academic centers

Narendranath Epperla, John Sharp, Natalie Grover et al. Nov 03, 2025 pp. 4533-4533 10.1182/blood-2025-4533

Abstract Introduction: Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin lymphoma characterized by relapses over patients' (pts...

Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma

Huihuang Yan, Aneta Mikulasova, Suganti Shivaram et al. Nov 03, 2025 pp. 3939-3939 10.1182/blood-2025-3939

Abstract Cyclin D1, encoded by CCND1, is a cell cycle regulator, overexpressed in ~15% of multiple myeloma (MM) cases via CCND1::IGH super-e...

Clonal hematopoiesis drives T cell dysregulation and immune remodeling revealed by GWAS-based mendelian randomization and single-cell transcriptomics

Richard Qin, Shivani Kapadia, Kernyu Park et al. Nov 03, 2025 pp. 1396-1396 10.1182/blood-2025-1396

Abstract Clonal hematopoiesis (CH), driven by somatic mutations in hematopoietic stem and progenitor cells (HSPCs), is associated with incre...

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

Eytan Stein, Alice Mims, Zhuoer Xie et al. Nov 03, 2025 pp. 1655-1655 10.1182/blood-2025-1655

Abstract Background: Dysregulated alternative splicing (AS) is hallmark of cancer which plays an important role in regulating proliferation,...

Sociodemographic and patient-related determinants of outcomes after unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis

Moazzam Shahzad, Aqeeb Ur Rehman, Shah Rukh et al. Nov 03, 2025 pp. 7684-7684 10.1182/blood-2025-7684

Abstract Background Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for several hematologic disorders. While...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page